Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 5/20 | 0.39 |
| ▸ | NPY2R | P49146 | 7/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849662 | 0.80 | RAMP1 (0.41) | ADRB2EPHX2RAMP1CALCRL | |
| SCHEMBL5248989 | 0.80 | RAMP1 (0.42) | TEAD1ADRB2OPRL1EPHX2RAMP1 | |
| SCHEMBL4718767 | 0.77 | ADRB2 (0.37) | ADRB2EPHX2RAMP1CALCRL | |
| SCHEMBL4720727 | 0.77 | ADRB2 (0.37) | ADRB2EPHX2RAMP1CALCRL | |
| SCHEMBL4798589 | 0.76 | TEAD1 (0.36) | TEAD1ADRB2EPHX2RAMP1CALCRL | |
| SCHEMBL5326014 | 0.71 | ACACB (0.35) | TEAD1RAMP1CALCRL | |
| SCHEMBL4720816 | 0.69 | RAMP1 (0.35) | ADRB2RAMP1CALCRL | |
| SCHEMBL4763044 | 0.66 | NOTUM (0.34) | — | |
| SCHEMBL5250813 | 0.65 | CCR3 (0.38) | — | |
| SCHEMBL4804847 | 0.65 | OPRD1 (0.43) | ADRB2EPHX2RAMP1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439237-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | TEAD1 1640/4885NPY2R 20/4885ADRB2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.